Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
52 Week high
52 Week low
Barrons • 2 days ago • AMGNAmgen Stock Was a Winner in the Third Quarter. These Solar Shares Were Not.
InvestorPlace • 3 days ago • AMGN3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
Proactive Investors • 4 days ago • AMGNNeumora Therapeutics stock surges as Amgen confirmed as major holder of the novel depression drug developer
Market Watch • 4 days ago • AMGNAmgen discloses more than $400 million stake in recent IPO Neumora Therapeutics
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.